Skip to Main Content
Open, not recruiting

ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors

About this study

There are very few, effective treatments for aggressive pediatric brain and solid tumors. These tumors include those that come back after treatment, also known as recurrent, and tumors that don’t respond to therapy, also known as refractive. 

Researchers have tested new, experimental drugs to find a treatment that may fight these kinds of tumors better. One of those drugs is called selinexor, also known as KPT-330. Selinexor has shown promise in fighting cancer in test tubes and animals. It has also been used in adults with no severe side effects, but doctors don’t yet know if younger patients will respond in the same way. St. Jude is offering this Phase I study to see how selinexor can benefit children, adolescents and young adults with these kinds of tumors.

Eligibility overview

  • Diagnosis of solid tumor that did not respond to treatment or came back after treatment, including lymphoma and central nervous system tumors
  • At least 1 but not more than 21 years of age
  • Able to swallow tablets whole

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

A Phase I Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Study goal:

The main goal of this study is to find out how much selinexor may be given safely to children who have these kinds of aggressive tumors without causing severe side effects. Researchers also want to find out how well selinexor treats these tumors and want to learn more about the drug’s effects on the rest of the body.


Solid tumors

Clinical trials categories:

Childhood Cancer Solid Tumors

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more